Naftazone is a naphtoquinone derivative which was originally registered in several European countries for treating symptoms of varicose veins and venous insufficiency, based on its venoconstrictive properties. ts venotonic mechanism of action remains unknown, but the drug has anti‐inflammatory effects and inhibits platelet aggregation. Naftazone is shown to accelerate human saphenous vein endothelial cell proliferation in vitro at concentrations which did not alter the hemostatic balance. Naftazone, which exhibits glutamate release inhibition properties, has shown antiparkinsonian and antidyskinetic activity in preclinical models of Parkinson's disease and in a clinical proof of concept study. Naftazone is currently marketed in several countries.

Tribenoside, a glucofuranoside derivative has been shown to have potent anti-allergic and anti-inflammatory properties. It has been reported to display a pluripotent antagonistic action against histamine, serotonin, bradykinin and other inflammatory substances. Tribenoside decrease capillary permeability, thus reducing edema. Tribenoside combat the pathological processes of capillaries and veins. It is used in adults and adolescents for treatment of venous circulation diseases. Although Tribenoside is derived from a sugar substance, it doesn’t affect the carbohydrate metabolism even in diabetics. Tribenoside might cause some side effects such as skin redness, headache. Very rare cases are: systemic anaphylaxis, including urticaria, angioedema.